autologous melanoma cell vaccine

**Autologous melanoma cell vaccine** is a personalized immunotherapy prepared from a patient's own melanoma cells, typically harvested from a tumor specimen, processed ex vivo (sometimes cultured), modified (e.g., conjugated with dinitrophenyl, or genetically engineered to secrete granulocyte-macrophage colony-stimulating factor/GM-CSF), lethally irradiated, and then administered back to the patient as an adjuvant or therapeutic vaccine for melanoma. The goal is to present a wide array of tumor-associated antigens in the context of the patient's own major histocompatibility complex (MHC) molecules, thereby stimulating a tumor-specific T cell immune response. Response to therapy (e.g., via delayed-type hypersensitivity to unmodified melanoma cells) appears closely correlated with improved disease-free and overall survival, especially in the adjuvant (post-resection) setting for stage III and IV melanoma patients[1][2][3][5].

Other names

autologous melanoma vaccineautologous melanoma cell-based vaccineautologous tumor cell vaccine (melanoma)